Is Humacyte, Inc. (HUMAW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | 12.0% / 33% | 32.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | 12.0% / 33% | 32.6% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -6603.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -52.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$98M |
| Free Cash Flow | -$100M |
| Total Debt | $17M |
| Debt-to-Equity | 2101.8 |
| Current Ratio | 3.7 |
| Total Assets | $138M |
Price & Trading
| Last Close | $0.09 |
| Beta | 1.9 |
|
52-Week Range
$0.09
| |
About Humacyte, Inc. (HUMAW)
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Related Halal Stocks in
Frequently Asked Questions
Is Humacyte, Inc. (HUMAW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Humacyte, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Humacyte, Inc.'s debt ratio?
Humacyte, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.0%.
What are Humacyte, Inc.'s key financial metrics?
Humacyte, Inc. has a market capitalization of N/A.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.